<div id="readability-page-1"><p>Erasca, Inc. (NASDAQ:ERAS - Free Report) - Equities research analysts at HC Wainwright upped their FY2027 earnings estimates for shares of Erasca in a report issued on Tuesday, January 13th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings of ($0.40) per share for the year, up from their previous estimate of ($0.44). HC Wainwright currently has a &#34;Buy&#34; rating and a $11.00 target price on the stock. The consensus estimate for Erasca's current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Erasca's FY2028 earnings at ($0.27) EPS, FY2029 earnings at ($0.09) EPS and FY2030 earnings at ($0.02) EPS.</p><p>Erasca (NASDAQ:ERAS - Get Free Report) last issued its earnings results on Wednesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.11). </p><p>Several other research firms have also recently commented on ERAS. Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of Erasca in a research report on Wednesday, October 8th. Mizuho raised their target price on Erasca from $4.00 to $5.00 and gave the company an &#34;outperform&#34; rating in a research report on Tuesday, December 9th. Piper Sandler started coverage on Erasca in a research report on Wednesday, January 7th. They set an &#34;overweight&#34; rating and a $5.00 price target for the company. Guggenheim upped their price objective on shares of Erasca from $3.00 to $5.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, November 14th. Finally, Morgan Stanley  set a $4.00 target price on shares of Erasca in a research note on Thursday, January 8th. Seven analysts have rated the stock with a Buy rating, one  has assigned  a Hold rating and two have issued  a Sell rating to the company. Based on data from MarketBeat.com, the company  has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $5.44.</p><p><b>Get Our Latest Stock Analysis on Erasca</b></p><h2>Erasca Stock Performance</h2><p>ERAS stock opened at $8.23 on Thursday. Erasca has a 1 year low of $1.01 and a 1 year high of $8.45. The stock's fifty day moving average is $3.58 and its two-hundred day moving average is $2.42. The stock has a market capitalization of $2.34 billion, a price-to-earnings ratio of -18.18 and a beta of 1.15. </p><h2>Hedge Funds Weigh In On Erasca</h2><p>Several institutional investors and hedge funds have recently modified their holdings of the stock. Frazier Life Sciences Management L.P. boosted its position in  Erasca by 0.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 22,729,436 shares of the company's stock worth $28,866,000 after purchasing an additional 153,585 shares during the period.  VR Adviser LLC increased its holdings in  Erasca by 10.1% in the 2nd quarter. VR Adviser LLC now owns 17,857,083 shares of the company's stock valued at $22,678,000 after buying an additional 1,640,867 shares during the period.  Paradigm Biocapital Advisors LP lifted its stake in  Erasca by 13.9% during the third quarter. Paradigm Biocapital Advisors LP now owns 13,560,017 shares of the company's stock worth $29,561,000 after purchasing an additional 1,652,835 shares during the period.  Vanguard Group Inc. boosted its holdings in  Erasca by 0.9% during the third quarter. Vanguard Group Inc. now owns 12,811,832 shares of the company's stock valued at $27,930,000 after purchasing an additional 116,235 shares in the last quarter.  Finally, Vivo Capital LLC grew its position in  Erasca by 37.2% in the third quarter. Vivo Capital LLC now owns 9,273,428 shares of the company's stock valued at $20,216,000 after acquiring an additional 2,516,672 shares during the period. 67.78% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>Insider Activity at Erasca</h2><p>In other news, General Counsel Ebun Garner sold 120,000 shares of the firm's stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $5.59, for a total transaction of $670,800.00. Following the completion of the sale, the general counsel directly owned 25,076 shares of the company's stock, valued at $140,174.84. This trade represents a 82.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own  14.40% of the company's stock. </p><h2>Erasca Company Profile</h2> (Get Free Report)<p>Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca's approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.  </p><p>Erasca's pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Erasca</li><li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li><li>How a Family Trust May Be Able To Help Preserve Your Wealth</li><li>A U.S. “birthright” claim worth trillions - activated quietly</li><li>Executive Order 14330: Trump’s Biggest Yet</li><li>First Time Since 2007: All Warnings Active</li></ul> <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVJBUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVJBUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Erasca Right Now?</h2><p>Before you consider Erasca, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Erasca wasn't on the list.</p><p>While Erasca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ERAS

<p>Erasca, Inc. (NASDAQ:ERAS) has had its FY2027 earnings forecast raised by HC Wainwright, with estimates now at ($0.40) per share, up from ($0.44). The firm maintains a "Buy" rating and a target price of $11.00. The consensus estimate for the current full-year earnings is ($0.73) per share. Other analysts have varied ratings, with a consensus rating of "Moderate Buy" and a target price of $5.44. Erasca's stock opened at $8.23, with a market cap of $2.34 billion and significant institutional ownership.</p>

FY2027 Earnings Forecast for Erasca Issued By HC Wainwright